New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
06:19 EDTLLYEli Lilly announces unfavorable court ruling in Altima patent lawsuit
Eli Lilly announced that the English High Court has determined that the vitamin dosage regimen patents for Alimta would not be infringed by a generic competitor that has stated an intent to market certain alternative salt forms of pemetrexed in several European countries upon expiry of the Alimta compound patents in 2015. The decision came in the case of Actavis UK Limited and others v. Eli Lilly. The English court ruled that Alimta's vitamin dosage regimen patent would not be infringed by a generic competitor that had stated its intent to market certain alternative salt forms of pemetrexed in the United Kingdom prior to the U.K. patent's expiration in mid-2021. In addition, the English court granted corresponding declarations of non-infringement regarding Alimta's vitamin dosage regimen patents in France, Italy and Spain. Lilly plans to seek permission to appeal today's ruling to the Court of Appeal. The compound patents for Alimta in major European countries remain in force and are expected to provide exclusivity through 2015. In a parallel infringement case on one of the alternative salt forms of pemetrexed earlier this year, the Regional Court of Dusseldorf in Germany ruled in Lilly's favor regarding infringement of Alimta's vitamin dosage regimen patent under German law. Lilly agrees with the decision in Germany, which is currently under appeal.
News For LLY From The Last 14 Days
Check below for free stories on LLY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
07:12 EDTLLYEli Lilly announces results from pivotal UNCOVER studies for ixekizumab
Eli Lilly announces that its investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies. Patients treated with both dosing regimens of ixekizumab had significantly greater levels of skin clearance compared to placebo and to etanercept at the 12-week endpoint. Skin clearance was measured by standard primary endpoints for psoriasis studies: the Psoriasis Area and Severity Index and the Static Physician Global Assessment. For patients treated with ixekizumab either every four weeks or every two weeks, between 78 to 90 percent of patients achieved at least a 75 percent reduction in PASI score at 12 weeks. Additionally, 31 to 41 percent of these patients achieved PASI 100, or clear skin, at week 12. For comparison, between 5 to 7 percent of patients treated with etanercept in the UNCOVER-2 and 3 studies achieved PASI 100. Adverse events were comparable for patients receiving ixekizumab in the 12-week, randomized control portion across all three studies.
August 18, 2014
17:37 EDTLLYFDA grants tentative approval for Lilly, Boehringer Basaglar insulin
Subscribe for More Information
11:41 EDTLLYCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 11, 2014
11:58 EDTLLYMannKind rallies after inking licensing agreement with Sanofi
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use